Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9925252-B2
Publication Date
2018-03-27
Expiration Date
Abstract
Multilayer films are described that include polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria, fungus or parasite.
Core Innovation
The patent describes antigenic electrostatic multilayer film vaccines formed by electrostatic layer-by-layer assembly using oppositely charged polyelectrolyte layers. One polyelectrolyte layer includes an antigenic polyelectrolyte comprising a covalently linked viral, bacterial, fungal or parasite polypeptide epitope, presented as a designed peptide or polypeptide within a polyelectrolyte multilayer film.
The multilayer film further comprises a Toll-like receptor (TLR) ligand that is covalently linked to the antigenic polyelectrolyte, and the TLR ligand is not a lipoprotein or a lipopeptide. Multiple architectures for presenting the epitope and the TLR ligand in relation to the multilayer are described, including covalent linkage on the same or different polyelectrolytes or layers, and configurations in which multilayer films are mixed or a TLR ligand is deposited on a core prior to film build.
The polyelectrolyte multilayer uses polycationic or polyanionic materials with molecular weight greater than 1,000 and at least 5 charges per molecule. The patent discusses covalent attachment and formulation options including depositing the multilayer film onto core particles, and provides representative antigenic epitope and TLR ligand examples spanning TLR1/2/3/4/5/7/8/9.
Claims Coverage
The independent claim defines a composition with a first multilayer film containing a covalently linked antigenic polyelectrolyte epitope and a covalently linked TLR ligand, where the polyelectrolyte materials meet specified molecular weight and charge criteria. The inventive features are refined by dependent claims adding further TLR ligand options, specified TLR receptor binding targets, and multilayer deposition configurations including core particle deposition and additional multilayer films bearing different antigenic epitopes.
Antigenic multilayer film with covalently linked epitope polyelectrolyte
A first multilayer film comprising a plurality of oppositely charged polyelectrolyte layers, where one polyelectrolyte layer comprises a first antigenic polyelectrolyte comprising a covalently linked viral, bacterial, fungal or parasite polypeptide epitope.
Covalently linked non-lipoprotein/non-lipopeptide TLR ligand
The multilayer film comprises a toll-like receptor (TLR) ligand covalently linked to the first antigenic polyelectrolyte, wherein the TLR ligand is not a lipoprotein or a lipopeptide.
High molecular weight, highly charged polyelectrolytes
The polyelectrolytes in the multilayer film comprise a polycationic material or a polyanionic material having a molecular weight of greater than 1,000 and at least 5 charges per molecule.
Multilayer film deposited on a core particle
The first multilayer film is deposited onto a core particle.
Additional multilayer film with different epitope antigenic polyelectrolyte
The composition further comprises a second multilayer film with oppositely charged polyelectrolyte layers, where at least one layer contains a second antigenic polyelectrolyte with a viral, bacterial, fungal or parasite polypeptide epitope that differs from the first antigenic polypeptide epitope(s).
Overall, the claim coverage is directed to an electrostatic multilayer film composition in which a covalently linked antigenic polypeptide epitope is incorporated into an antigenic polyelectrolyte layer and a covalently linked, non-lipoprotein/non-lipopeptide TLR ligand is linked to that antigenic polyelectrolyte, using specified high molecular weight, highly charged polyelectrolytes. Additional claim refinements add core deposition and the ability to include a second multilayer film carrying a different antigenic epitope.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?